EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Mechanisms of Fuling Zexie decoction against metabolic dysfunction-associated steatotic liver disease: Integrative metabolomics, gut microbiota and serum pharmacochemistry

Peng-Quan Wang, Huan Yang, Yan-Mei Tang, Yu-Xuan Tao, Shao-Cong Han, Qi-Di Zhou, Jie Yu, Xing-Xin Yang

World Journal of Gastroenterology · 2027-01-07 · 33 (1)

DOI: 10.3748/wjg.123034 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) currently lacks specific therapeutic options. Fuling Zexie decoction (FZD) is a Chinese herbal formula that shows potential for treating MASLD, but its mechanism and active ingredients remain unclear. AIM To determine the mechanism and active ingredients of FZD against MASLD. METHODS Free fatty acid-stimulated steatotic HepG2 cells and high-fat diet-fed MASLD rats were used to assess the functionality of FZD. To investigate the mechanisms by which FZD affects endogenous metabolites and intestinal microbiota in rats, a combination of metabolomics and 16S rRNA sequencing was utilized. Serum pharmacochemistry-metabolomics integration identified FZD’s active ingredients and core targets, while molecular docking and cellular experimentation were utilized to validate the association of these ingredients and targets. RESULTS FZD ameliorated hepatic steatosis and hepatocellular injury in rats with MASLD, ameliorated serum and hepatic lipid levels, augmented antioxidant capacity, and mitigated inflammatory responses. Mechanistically, FZD restored 226 endogenous metabolites and regulated 17 metabolic pathways. This included reducing the Firmicutes/Bacteroidota ratio and diminishing the levels of potentially harmful microbes (Unclassified_f_Lachno spiraceae , Candidatus Saccharimonas , and Turicibacter ). A total of 39 FZD-originated constituents were detected in the serum. Among these, 24 were recognized as key pharmacodynamic constituents that modulated 17 targets, 10 metabolic pathways, and 18 endogenous metabolites. The key pharmacodynamic compound group downregulated the expression of NOS2 , MAOA , and MIF , thereby alleviating hepatic steatosis. CONCLUSION These results demonstrate that FZD alleviates MASLD by regulating 10 metabolic pathways, decreasing the abundance of Unclassified_f_Lachnospiraceae , Candidatus Saccharimonas , and Turicibacter , and normalizing 18 endogenous metabolite levels, which may be primarily attributed to the 24 FZD-derived active ingredients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →